Clearmind Medicine (CMND) announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder. The first patient was enrolled at Yale School of Medicine’s Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Mike Davis to become CDER deputy director, Pink Sheet’s Gingery says
- Clearmind notes partnership with political firm to promote psychedelics
- Clearmind Medicine adds Tel Aviv Sourasky Medical Center to ongoing AUD trial
- Trump Trade: President said to weigh possible U.S. strike against Iran
- Psychedelic advocates hopeful Trump administration will support space, STAT says